DDInter1018 DDInter1658
Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its possible use as a laxative for the treatment of chronic constipation did not occur until the 1960s and its first clinical use for treating PSE was not until 1966. Nevertheless, although lactulose received formal FDA approval in 1977 and has since become a readily available generic and brand-name non-prescription medication listed on the World Health Organization's List of Essential Medicines as one of the most effective and safe medicines employed in a health system, data regarding its optimal place in therapy is often ambiguous. Especially considering the use of lactulose as a laxative is typically only considered after lifestyle and dietary modifications fail and the
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Lactulose {u} (Compound) resembles {v} (Compound) Kanamycin
Lactulose {u} (Compound) resembles {v} (Compound) Acarbose
Lactulose {u} (Compound) is included by {v} (Pharmacologic Class) Acidifying Activity
Lactulose {u} (Compound) causes {v} (Side Effect) Abdominal discomfort
Lactulose {u} may cause a minor interaction that can limit clinical effects when taken with {v} Neomycin
Lactulose {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perflutren
Lactulose {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ofloxacin
Lactulose (Compound) resembles Kanamycin (Compound)
Lactulose (Compound) resembles Acarbose (Compound)
Lactulose (Compound) is included by Acidifying Activity (Pharmacologic Class)
Lactulose (Compound) causes Abdominal discomfort (Side Effect)
Lactulose may cause a minor interaction that can limit clinical effects when taken with Neomycin
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Perflutren
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin